134 related articles for article (PubMed ID: 37856040)
21. Elevated serum lactate dehydrogenase to albumin ratio is a useful poor prognostic predictor of nivolumab in patients with non-small cell lung cancer.
Menekse S; Kut E; Almuradova E
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):86-94. PubMed ID: 37869953
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and predictive value of histogram analysis in patients with non-small cell lung cancer refractory to platinum treated by nivolumab: A multicentre retrospective study.
Ravanelli M; Agazzi GM; Milanese G; Roca E; Silva M; Tiseo M; Rondi P; Baggi A; Ganeshan B; Muri M; Panni S; Botti C; Sverzellati N; Maroldi R; Berruti A; Farina D
Eur J Radiol; 2019 Sep; 118():251-256. PubMed ID: 31439251
[TBL] [Abstract][Full Text] [Related]
23. Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.
Hurkmans DP; Basak EA; Schepers N; Oomen-De Hoop E; Van der Leest CH; El Bouazzaoui S; Bins S; Koolen SLW; Sleijfer S; Van der Veldt AAM; Debets R; Van Schaik RHN; Aerts JGJV; Mathijssen RHJ
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461348
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of integrated
Umeda Y; Morikawa M; Anzai M; Ameshima S; Kadowaki M; Waseda Y; Shigemi H; Tsujikawa T; Kiyono Y; Okazawa H; Ishizuka T
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345624
[TBL] [Abstract][Full Text] [Related]
25. Clinical utility of the C-reactive protein:albumin ratio in non-small cell lung cancer patients treated with nivolumab.
Araki T; Tateishi K; Sonehara K; Hirota S; Komatsu M; Yamamoto M; Kanda S; Kuraishi H; Hanaoka M; Koizumi T
Thorac Cancer; 2021 Mar; 12(5):603-612. PubMed ID: 33434414
[TBL] [Abstract][Full Text] [Related]
26. Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer.
Kaneda T; Kurata T; Yoshida T; Kibata K; Yoshioka H; Yanagimoto H; Takeda K; Yoshida T; Tsuta K
BMC Cancer; 2022 Feb; 22(1):154. PubMed ID: 35135489
[TBL] [Abstract][Full Text] [Related]
27. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
28. Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer.
Ramagopalan S; Gupta A; Arora P; Thorlund K; Ray J; Subbiah V
JAMA Netw Open; 2021 Nov; 4(11):e2134299. PubMed ID: 34767024
[TBL] [Abstract][Full Text] [Related]
29. Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors.
Ramdani HO; Falk M; Heukamp LC; Schatz S; Tiemann M; Wesseler C; Diehl L; Schuuring E; Groen HJM; Griesinger F
Pathol Res Pract; 2021 Nov; 227():153651. PubMed ID: 34673351
[TBL] [Abstract][Full Text] [Related]
30. Predictive resistance factors in lung cancer patients treated with Nivolumab. Retrospective study.
Bernichon E; Tissot C; Bayle-Bleuez S; Rivoirard R; Bouleftour W; Forest F; Tinquaut F; Mery B; Fournel P
Bull Cancer; 2021 Mar; 108(3):250-265. PubMed ID: 33358747
[TBL] [Abstract][Full Text] [Related]
31. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
32. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
[No Abstract] [Full Text] [Related]
33. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
[TBL] [Abstract][Full Text] [Related]
34. Observational study to predict the efficacy and optimal duration of nivolumab treatment in patients with previously treated advanced or recurrent non-small cell lung cancer.
Goto Y; Yoh K; Kato T; Hosomi Y; Usui K; Fukui T; Hirano K; Tanaka H; Taguri M; Kunitoh H
Jpn J Clin Oncol; 2023 Jan; 53(2):153-160. PubMed ID: 36300307
[TBL] [Abstract][Full Text] [Related]
35. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
36. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
37. Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidence.
Dudnik E; Moskovitz M; Agbarya A; Gottfried T; Shochat T; Urban D; Zer A; Rotem O; Moore A; Yust S; Peled N; Wollner M; Bar J;
Int J Cancer; 2021 Mar; 148(5):1183-1191. PubMed ID: 32875571
[TBL] [Abstract][Full Text] [Related]
38. Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma.
Wang R; Zheng J; Shao X; Ishii Y; Roy A; Bello A; Lee R; Zhang J; Wind-Rotolo M; Feng Y
J Immunother Cancer; 2019 Dec; 7(1):348. PubMed ID: 31829287
[TBL] [Abstract][Full Text] [Related]
39. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
[TBL] [Abstract][Full Text] [Related]
40. Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
Chmielewska I; Dudzińska M; Szczyrek M; Świrska J; Wojas-Krawczyk K; Zwolak A
PLoS One; 2021; 16(9):e0257484. PubMed ID: 34587185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
